Sistema de Salut de Catalunya
Institut Català de la Salut
[Baraibar I, Salvà F, Ros J, Saoudi N, García-Álvarez A, Hernando J, Capdevila J, Castells MR, Tabernero J, Élez E] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [García A, Comas R, Castillo G, Sanchis M] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martí M, Espín E, Dopazo C] Servei de Cirurgia General i Digestiva, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Landolfi S] Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Navalpotro B] Servei d’Oncologia Radioteràpica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Guevara J] Servei d’Aparell Digestiu, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Nuciforo P, Vivancos A] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-04-27T09:42:52Z
2023-04-27T09:42:52Z
2023-06
COVID-19 pandemic; Early-onset colorectal cancer
Pandemia de COVID-19 Cáncer colorrectal precoz
Pandèmia de COVID-19; Càncer colorectal precoç
The COVID19 pandemic has affected the spectrum of cancer care worldwide. Early onset colorectal cancer (EOCRC) is defined as diagnosis below the age of 50. Patients with EOCRC faced multiple challenges during the COVID19 pandemic and in some institutions it jeopardized cancer diagnosis and care delivery. Our study aims to identify the clinicopathological features and outcomes of patients with EOCRC in our Centre during the first wave of the pandemic in comparison with the same period in 2019 and 2021. Patients with EOCRC visited for the first time at Vall d'Hebron University Hospital in Spain from the 1st March to 31st August of 2019, 2020 and 2021 were included in the analysis. 177 patients with EOCRC were visited for the first time between 2019 and 2021, of which 90 patients met the inclusion criteria (2019: 30 patients, 2020: 29 patients, 2021: 31 patients). Neither differences in frequency nor in stage at diagnosis or at first visit during the given periods were observed. Of note, indication of systemic therapy in the adjuvant or metastatic setting was not altered. Days to treatment initiation and enrollment in clinical trials in this subpopulation was not affected due to the COVID-19 outbreak.
This work was supported by the Cancer Research UK (CRUK) grant OPTIMISTICC (C10674/A27140).
Article
Published version
English
Còlon - Càncer - Diagnòstic; Càncer - Detecció precoç; Recte - Càncer - Diagnòstic; COVID-19 (Malaltia); DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis::Early Detection of Cancer; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz::detección precoz del cáncer; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Elsevier
Translational Oncology;32
https://doi.org/10.1016/j.tranon.2023.101668
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3439]
